Home › Trial NCT04268706
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
- Trial IDNCT04268706
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorTessa Therapeutics
- Enrollment97
- Start date2021-02-01
- ConditionsHodgkin Lymphoma, Adult · Hodgkin Disease Recurrent · Hodgkin Disease Refractory · Hodgkin Disease, Pediatric
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.